You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Moodys
Baxter
Johnson and Johnson
Medtronic

Last Updated: September 27, 2023

Investigational Drug Information for INC280


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for INC280?

INC280 is an investigational drug.

There have been 38 clinical trials for INC280. The most recent clinical trial was a Phase 2 trial, which was initiated on September 22nd 2021.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Carcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, National Cancer Institute (NCI), and Novartis.

There are seventy-five US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for INC280
TitleSponsorPhase
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)National Cancer Institute (NCI)Phase 2
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Southwest Oncology GroupPhase 2
Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping MutationNovartisPhase 1

See all INC280 clinical trials

Clinical Trial Summary for INC280

Top disease conditions for INC280
Top clinical trial sponsors for INC280

See all INC280 clinical trials

US Patents for INC280

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
INC280 ⤷  Try a Trial Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA) ⤷  Try a Trial
INC280 ⤷  Try a Trial Methods of treating vestibular schwannoma and reducing hearing or neurite loss caused by vestibular schwannoma Massachusetts Eye and Ear Infirmary (Boston, MA) ⤷  Try a Trial
INC280 ⤷  Try a Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Try a Trial
INC280 ⤷  Try a Trial Methods of treating pediatric cancers Loxo Oncology, Inc. (Stamford, CT) ⤷  Try a Trial
INC280 ⤷  Try a Trial Combination therapy using c-Met inhibitor and IGF-1R inhibitor for c-Met inhibitor resistant cancers SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR) YONSEI UNIVERSITY, UNIVERSITY-INDUSTRY FOUNDATION (UIF) (Seoul, KR) ⤷  Try a Trial
INC280 ⤷  Try a Trial Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide Novartis AG (Basel, CH) ⤷  Try a Trial
INC280 ⤷  Try a Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for INC280

Drugname Country Document Number Estimated Expiration Related US Patent
INC280 European Patent Office EP3131552 2034-04-16 ⤷  Try a Trial
INC280 Spain ES2823756 2034-04-16 ⤷  Try a Trial
INC280 Japan JP2017514806 2034-04-16 ⤷  Try a Trial
INC280 Japan JP2019070012 2034-04-16 ⤷  Try a Trial
INC280 Japan JP2021059548 2034-04-16 ⤷  Try a Trial
INC280 Japan JP6838085 2034-04-16 ⤷  Try a Trial
INC280 New Zealand NZ629860 2034-04-16 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Moodys
Baxter
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.